This initiative has been built based on the NSTEDB s past experience.
Indian startups and companies have been invited to apply for developing new technologies.
New Delhi: The Department of Science and Technology (DST) has invited applications from startups and companies for developing new technologies and innovative products to tackle the second wave of the COVID-19 pandemic.
Under NIDHI4COVID2.0 initiative by the DST, companies and startups registered in India, offering promising solutions in the thrust areas of oxygen innovation, portable solution, relevant medical accessories, diagnostic, informatics, or any other solution that addresses or mitigates various challenges faced by the country or society due to the severity are eligible for funding.
PathShodh has received the license to manufacture the test for sale from the CDSCO, after due diligence validation at the Translational Health Science and THSTI, Faridabad, as per the requirements of the ICMR.
A COVID-19 test developed by PathShodh Healthcare
A COVID-19 test developed by PathShodh Healthcare, a start-up incubated at the Society for Innovation and Development (SID), Indian Institute of Science (IISc),
has received the license to manufacture the test for sale from the Central Drugs Standard Control Organisation (CDSCO).
The test is touted to be the first-of-its-kind, semi-quantitative electrochemical ELISA test for COVID-19 IgM and IgG antibodies, received the licence after due diligence validation at the Translational Health Science and Technology Institute (THSTI), Faridabad, as per the requirements of the Indian Council of Medical Research (ICMR), an IISc release said.
According to the release, the novelty of the technology is based on the measurement of electrochemical redox activity of IgM and IgG antibodies specific to the SARS-CoV-2 Spike Glycoprotein (S1). The S1 protein has a Receptor Binding Domain (RBD) which latches on to the ACE2 receptors on the host
May 19, 2021
×
‘Capability to quantify the Covid-19 antibody concentration will be crucial in estimating the declining antibody response over time’
PathShodh Healthcare, a start-up incubated at the Society for Innovation and Development (SID), Indian Institute of Science (IISc), has developed a semi-quantitative electrochemical ELISA test for Covid-19 IgM and IgG antibodies.
PathShodh has received the licence to manufacture the test for sale from the Central Drugs Standard Control Organisation (CDSCO), after due diligence validation at the Translational Health Science and Technology Institute (THSTI), Faridabad, as per the requirements of the Indian Council of Medical Research (ICMR).
The novelty of the technology is based on the measurement of electrochemical redox activity of IgM and IgG antibodies specific to the SARS-CoV-2 Spike Glycoprotein (S1).
DST supported startup develops affordable test kits for early diagnosis of Covid-19 in rural & resource constraint areas
A Mumbai-based startup is ready with its affordable
Rapid Antigen Test that offers
COVID 19 diagnosis & surveillance at the cost of Rs 100 per test.
The test developed by
Patanjali Pharma will complement the gold standard RTPCR & Rapid antigen tests and make it one of the most affordable ones available in the market.
The Centre for Augmenting WAR with COVID-19 Health Crisis (CAWACH), an initiative by the
Department of Science and Technology (
DST), supported the startup in July, 2020 to develop Rapid Covid 19 diagnostics (both Rapid antibody and antigen tests for surveillance and early diagnosis of Covid- 19, respectively).